BioSpace News Archive

Amedisys, Inc., one of the nation’s leading home healthcare, hospice and personal care companies, celebrates National Nurses Week by honoring the thousands of nurses who call the company home.

The national distribution partnership aims to help employers manage healthcare costs through a combination of One Medical’s modernized primary care with ParetoHealth’s self-insured employee benefit solution

Prime Therapeutics LLC’s President and CEO Ken Paulus is joining over 2,000 other chief executive officers by signing the CEO Action for Diversity & Inclusion pledge.

Vivos Therapeutics, Inc., a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea, announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its first quarter 2021 financial results and provided a business update.

BIOLASE, Inc., the global leader in dental lasers, announced that it will release first quarter 2021 financial and operating results on Thursday, May 13, 2021 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced positive data from the first two dose cohorts of Part 2 of its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC)

Nephros, Inc., a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, announced results for the three months ended March 31, 2021.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent developments.